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Abstract
Background: Colorectal carcinoma is one of the major causes of morbidity and mortality in the
Western World. Novel therapeutic approaches are needed for colorectal carcinoma. Curcumin,
the active component and yellow pigment of turmeric, has been reported to have several anti-
cancer activities including anti-proliferation, anti-invasion, and anti-angiogenesis. Clinical trials have
suggested that curcumin may serve as a potential preventive or therapeutic agent for colorectal
cancer.
Methods: We compared the inhibitory effects of curcumin and novel structural analogues, GO-
Y030, FLLL-11, and FLLL-12, in three independent human colorectal cancer cell lines, SW480, HT-
29, and HCT116. MTT cell viability assay was used to examine the cell viability/proliferation and
western blots were used to determine the level of PARP cleavages. Half-Maximal inhibitory
concentrations (IC50) were calculated using Sigma Plot 9.0 software.
Results: Curcumin inhibited cell viability in all three of the human colorectal cancer cell lines
studied with IC50 values ranging between 10.26 μM and 13.31 μM. GO-Y030, FLLL-11, and FLLL-
12 were more potent than curcumin in the inhibition of cell viability in these three human
colorectal cancer cell lines with IC50 values ranging between 0.51 μM and 4.48 μM. In addition,
FLLL-11 and FLLL-12 exhibit low toxicity to WI-38 normal human lung fibroblasts with an IC-50
value greater than 1,000 μM. GO-Y030, FLLL-11, and FLLL-12 are also more potent than curcumin
in the induction of apoptosis, as evidenced by cleaved PARP and cleaved caspase-3 in all three
human colorectal cancer cell lines studied.
Conclusion: The results indicate that the three curcumin analogues studied exhibit more potent
inhibitory activity than curcumin in human colorectal cancer cells. Thus, they may have translational
potential as chemopreventive or therapeutic agents for colorectal carcinoma.
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Background
In the United States, colorectal cancer is the third most fre-
quently occurring cancer in both sexes and overall is the
second leading cause of cancer deaths. The lifetime prob-
ability of developing colorectal cancer is about 5% in the
United States. Despite advances in the treatment of color-
ectal cancer, the five-year survival rate has only increased
to 65% [1]. Hence, better approaches for the prevention
and treatment of colorectal cancer are needed.
Curcumin has been shown to protect against carcinogen-
esis and to prevent tumor formation and development in
several cancer types. It has also been shown to suppress
angiogenesis and metastasis in a variety of animal tumor
models [2-6]. Curcumin is a bioactive component found
in the rhizome of the perennial herb Curcuma longa. A
polyphenolic compound with intense yellow coloring,
curcumin has been part of therapeutic preparations for
centuries due to its wide spectrum of beneficial activities
and its safety in relatively large doses [7]. Extensive
research has indicated that the complex chemistry of cur-
cumin allows it to influence multiple cell signaling path-
ways, giving it anti-inflammatory, antioxidant,
chemopreventive, and chemotherapeutic properties in
addition to many others [8]. The anti-carcinogenic prop-
erties of curcumin continue to be a subject of great inter-
est. Evidence that it can inhibit the initiation, progression,
and continued survival of cancerous cells, likewise, con-
tinues to accumulate [8]. Curcumin inhibits cell prolifer-
ation by interfering with the cell cycle and inducing
apoptosis in colorectal carcinoma cells [9,10]. Curcumin
also has chemopreventive potential for colorectal cancer
as seen in a mouse model and in human clinical trials
[4,8,11,12].
Despite promising findings, curcumin has yet to be
approved as an effective chemotherapeutic agent. Testing
in animal models and human clinical trials has revealed
that the bioavailability of curcumin is low, owing to its
poor absorption across the gut, limited tissue distribution,
rapid metabolism, and its subsequent elimination from
the body [13]. In light of these findings, numerous strate-
gies have been devised to address the limitations of curcu-
min, including the design and synthesis of novel
structural analogues [14]. One such compound is GO-
Y030 [15] and two other compounds, FLLL-11 and FLLL-
12, which were synthesized by our laboratories. In our
present study, we compared the inhibitory efficacy of GO-
Y030, FLLL-11, FLLL-12, and curcumin in human colorec-
tal cancer cell lines. We demonstrated that GO-Y030,
FLLL-11, and FLLL-12 are more active than curcumin in
the inhibition of cell proliferation and induction of PARP
and caspase-3 cleavages in all three colorectal cancer cell
lines. GO-Y030 appears to be slightly more potent than
FLLL-11 and FLLL-12 in these colorectal cancer cell lines.
Therefore, the synthetic derivatives of curcumin studied
have potential as new therapeutic agents for colorectal
cancer.
Methods
Cell Culture
Human colorectal cancer cells, HCT-116, SW480, and HT-
29, WI-38 human lung fibroblasts, and MCF-10A immor-
talized human mammary epithelial cells were acquired
from the American Type Culture Collection (ATCC). The
cancer cells were maintained in 1× Dulbecco's Modifica-
tion of Eagle's Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) (Invitrogen), 4.5 g/L L-
glutamine and sodium pyruvate (Mediatech), and 1%
Penicillin/Streptomycin (P/S). The cells were kept in a
humidified 37°C incubator and aired with 5% CO2. The
MCF-10A cells were maintained in Ham's F12 media
(Mediatech) supplemented with 5% FBS, 5 μg/ml insulin,
1 μg/ml hydrocortisone, 10 μg/ml epidermal growth fac-
tor (EGF), 100 μg/ml cholera toxin, and 1% P/S. Normal
human bladder smooth muscle cells (HdSMC) were pur-
chased from Lonza (Walkersville, MD) and Normal
human colonic smooth muscle cells (HCSMC) were pur-
chased from ScienCell (Carlsbad, CA).
Western blot analysis
HCT-116, SW480, and HT-29 colorectal cancer cells, WI-
38, HdSMC, HCSMC, and MCF-10A cells were treated
with the listed concentrations of GO-Y030, FLLL-11,
FLLL-12, and Curcumin (Sigma-Aldriich, St. Louis, MO)
for 24 hours. Total protein lysates (50 μg/lane), as deter-
mined by BCA Protein Assay Kit (Thermo Fisher Scientific,
Rockford, IL), were separated by 10% SDS-polyacryla-
mide gels and transferred to membranes. Membranes
were blotted with a 1:1000 dilution of antibodies against
cleaved Poly (ADP-ribose) polymerase (PARP) (Asp214)
and cleaved caspase-3 (Asp175) (Cell Signaling Technol-
ogy, Beverly, MA). A 1:1000 dilution of anti-GAPDH
(glyceraldehydes-3-phosphoate dehydrogenase) mono-
clonal antibody (MAB374, Chemicon International, Inc.,
Temecula, CA) was used as a protein loading control. The
blots were incubated with a 1:600 dilution of secondary
fluorescein-linked anti-mouse or anti-rabbit antibody fol-
lowed by incubation with a 1:2500 dilution of alkaline
phosphatase conjugated anti-fluorescein antibody (Amer-
sham Biosciences, Piscataway, NJ). Blots were scanned
with ImageQuant software using an ECF Western blotting
detection system (Amersham Biosciences, Piscataway, NJ)
on a Molecular Dynamics Storm PhosphorImager (Sun-
nyvale, CA). The fluorescent signals were scanned and
documented using a Storm 860 scanner (Molecular
Dynamics, Sunnyvale, CA, USA).BMC Cancer 2009, 9:99 http://www.biomedcentral.com/1471-2407/9/99
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MTT Cell Viability Assay
HCT-116, SW480, and HT-29 human colorectal cancer
cells and WI-38 lung fibroblasts were seeded in 96-well
plates (4000 cells/well) in DMEM with 10% FBS. The fol-
lowing day the cells were treated with GO-Y030, FLLL-11,
FLLL-12, and Curcumin (Sigma-Aldriich, St. Louis, MO)
as indicated and incubated for 72 hours. 25 μl of MTT
(Thiazolyl Blue Tetrazolium Bromide: M5655, SIGMA)
was added to each well and incubated for 3.5 hours fol-
lowed by the addition of 100 μl of N,N-dimethylforma-
mide (D4551, SIGMA) solubilization solution. The plates
were left at room temperature overnight to allow com-
plete lysis of the cells and read at 450 nm the following
day. Half-Maximal inhibitory concentrations (IC50), the
drug concentration at which 50% growth inhibition is
achieved, was calculated using Sigma Plot 9.0 software
(Systat Software Inc., San Jose, CA) with the 4 parameter
logistic function standard curve analysis for dose
response.
Bright Field Microscopy
Colorectal cancer cells were seeded in six-well plates at a
density of 4 × 104 cells per well and incubated overnight
to allow the cells to adhere. The cells were treated with the
listed agents and incubated for four days. The cells were
washed briefly in PBS before being photographed using
bright field microscopy (10× magnification). Images were
taken with a Model 9.0 Monochrome-6 Camera on a com-
puter equipped with Spot Advanced imaging software
(Diagnostic Instruments Inc., Sterling Heights, MI). Three
images of each treatment were taken from randomly cho-
sen fields and a representative image was selected for dis-
play in the figure.
Results
New curcumin analogues are more potent than curcumin 
in inhibiting cell viability in human colorectal cancer cells
In this study, we examined the growth suppressive activi-
ties of three structural analogues of curcumin, GO-Y030,
FLLL-11, and FLLL-12 (Figures 1A and 1B), in three inde-
pendent human colorectal cancer cell lines, HCT-116,
SW480, and HT-29, as well as WI-38 lung fibroblasts. We
first examined the inhibitory effect of cell viability by cur-
cumin, GO-Y030, FLLL-11, and FLLL-12 in human color-
ectal cancer cell lines and WI-38 normal human lung
fibroblasts. After 72 hours of treatment, the percent of
inhibition was determined. GO-Y030, FLLL-11, and FLLL-
12 all exhibited greater levels of inhibition, when com-
pared to untreated cells in colorectal cancer cell lines than
curcumin (Figures 2A and 2B). Furthermore, FLLL-11 and
FLLL-12 had a low inhibitory effect on cell viability in WI-
38 human lung fibroblasts (Figure 2C). Representative
pictures of the inhibition of cell growth were taken for the
three colorectal cancer cell lines, SW480 (Figure 2D),
HCT116 and HT-29 (Data not shown). IC50 values were
calculated for each cell line and treatment (Table 1). The
results demonstrate that GO-Y030, FLLL-11, and FLLL-12
are more potent than curcumin in the growth suppression
of the human colorectal cancer cell lines studied.
GO-Y030, FLLL-11, and FLLL-12 are more potent than 
curcumin in inducing apoptosis in colorectal cancer cells
The induction of apoptosis was examined using cleaved
PARP (Asp214) and cleaved caspase-3 (Asp175) in
HCT116, SW480, and HT-29 colorectal cancer cells. GO-
Y030, FLLL-11, and FLLL-12 at 2.5 and 5 μM induced
cleaved PARP and cleaved caspase-3 in HCT116 colorectal
cancer cells as evidenced by increased levels of cleaved
PARP and cleaved caspase-3 while 10 and 20 μM of curcu-
min induced increased levels of cleaved PARP and cas-
pase-3 (Figure 3A). HT-29 colorectal cancer cells seem to
be the most resistance to curcumin and these three ana-
logues, 5 μM of GO-Y030, FLLL-11, and FLLL-12 induced
increased levels of cleaved PARP, whereas 10 and 20 μM
of curcumin did not exhibit increased levels of cleaved
PARP (Figure 3B). 5 μM of GO-Y030 and 20 μM of curcu-
min induced increased levels of cleaved caspase-3 while
slightly increased of cleaved caspase-3 was detected in
FLLL-11 and FLLL-12 treated HT-29 cells (Figure 3B). 20
μM of curcumin induced increased levels of cleaved PARP
(Figure 3C). FLLL-12 at 5 and GO-Y030 at 2.5 and 5 μM
induced increased levels of cleaved PARP and caspase-3 in
SW480 colorectal cancer cells (Figure 3C). 20 μM of cur-
cumin induced slightly increased levels of cleaved PARP
and caspase-3 in SW480 cancer cells (Figure 3C). The
results indicate that GO-Y030, FLLL-11, and FLLL-12 are
more potent than curcumin in inducing PARP and cas-
pase-3 cleavages in the three human colorectal cancer cell
lines studied. Further, GO-Y030, FLLL-11 and FLLL-12
(A) The chemical structures of curcumin, GO-Y030, FLLL- 11, and FLLL-12 Figure 1
(A) The chemical structures of curcumin, GO-Y030, 
FLLL-11, and FLLL-12. (B) Synthesis of FLLL-11, FLLL-12, 
and GO-Y030.
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The inhibitory effects of cell viability by (A) curcumin (Cur) and GO-Y030 (GY), (B) FLLL-11 and FLLL-12 in human colorectal  cancer cell lines, HCT116, HT-29, SW480, and (C) WI-38 normal human lung fibroblasts Figure 2
The inhibitory effects of cell viability by (A) curcumin (Cur) and GO-Y030 (GY), (B) FLLL-11 and FLLL-12 in 
human colorectal cancer cell lines, HCT116, HT-29, SW480, and (C) WI-38 normal human lung fibroblasts. 
Representative pictures in (D) SW480 colon cancer cells were shown.
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appear to induce PARP cleavages in normal human
colonic smooth muscle cells. However, GO-Y030, FLLL-
11, and FLLL-12 did not induce PARP cleavages in WI-38
normal human lung fibroblasts, normal human bladder
smooth muscle cells, and MCF-10A non-malignant
human mammary epithelial cells (Figures 3D and 3E).
Discussion
Current anticancer therapies tend to be inadequate in
terms of their therapeutic efficacy and the undesirable side
effects that they produce. Bioactive compounds, known as
phytochemicals, have been found to exhibit growth-sup-
pressive activity as well as chemopreventive properties
against various types of cancer [2]. Curcumin is one of the
most widely characterized phytochemicals and is the
active ingredient in the rhizome of the plant turmeric
(Curcuma longa). Curcumin has both antioxidant and
anti-inflammatory properties [2,3,16]. It has also been
shown to protect against carcinogenesis and in the pre-
vention of tumor formation and development in several
cancer types. In a variety of animal tumor models, curcu-
min has been found to suppress angiogenesis and metas-
tasis [2-6,17-21]. The growth suppressive activity and
bioavailability of curcumin in humans may be effective as
a preventive agent; however, it may not be sufficient as a
therapeutic agent in colorectal cancer. Analogues of curcu-
min, which exhibit increased potency, are needed as more
effective therapeutic agents for colorectal cancer treat-
ments.
There are several curcumin analogues that have already
been reported, such as dimethoxycurcumin and EF-24
[22-26]. We compared the inhibitory efficacy of new cur-
cumin analogues, GO-Y030, FLLL-11, and FLLL-12 in
colorectal cancer cell lines. We demonstrated that GO-
Y030, FLLL-11, and FLLL-12 are more potent than curcu-
min in the inhibition of cell viability/proliferation in all
three independent human colorectal carcinoma cell lines
studied. GO-Y030, FLLL-11, and FLLL-12 are also more
potent than curcumin in the induction of cleaved PARP,
evidence of apoptosis, in the colorectal cancer cells stud-
ied. Although, cleaved PARP was also observed in normal
colonic smooth muscle cells by GO-Y030, FLLL-11, and
FLLL-12, GO-Y030, FLLL-11, and FLLL-12 did not induce
cleaved PARP in WI-38 normal human lung fibroblasts,
normal bladder smooth muscle cells, and MCF-10A
immortalized, non-malignant, human mammary epithe-
lial cells. FLLL-11 and FLLL-12 appear to be slightly less
potent than GO-Y030 in the inhibition of cell viability in
the colorectal cancer cell lines studied. However, FLLL-11
and FLLL-12 have less inhibitory effects than GO-Y030 in
WI-38 normal human lung fibroblasts. FLLL-11 and FLLL-
12 are respectively, 223 and 298 fold times more toxic in
colorectal cancer cells than in WI-38 normal human lung
fibroblasts compared to GO-Y030 which is only 14 fold
times more toxic. Curcumin has been found to be safe in
clinical trials and dose-limiting toxicity was not observed
[27-30]. Similar to curcumin, FLLL-11 and FLLL-12 seem
to have low toxicity in WI-38 normal human lung fibrob-
lasts, normal bladder smooth muscle cells and non-malig-
nant MCF-10A mammary epithelial cells except FLLL-11,
FLLL-12, and GO-Y030 induce cleaved PARP in normal
colonic smooth muscle cells. It will be interested to eval-
uate the inhibitory efficacy of FLLL-11, FLLL-12, and GO-
Y030 to suppress the growth of the human colon tumor
cells in mouse model in vivo. Further, it will also be neces-
sary to evaluate the possible toxicity of FLLL-11, FLLL-12,
and GO-Y030 comparing to curcumin in mice without
tumors in vivo in particular in colon to verify the toxicity
we have observed in normal colonic smooth muscle cells.
To evaluate the possible drug-likeness of these curcumin
analogues, we used QikProp (Schrodinger LLC) to com-
pute the absorption, distribution, metabolism, excretion
and toxicity (ADME/Tox) properties of curcumin, FLLL-
11, FLLL-12 and GO-Y030. Overall, fifty "drug-likeness"
parameters have been calculated, covering molecular
weight, polarity, solubility, cell permeability, blood brain
barrier, HERG K+ blockage, HSA binding and metabolic
stability, etc. For curcumin itself, the prediction shows
concern on potential HERG K+ channel blockage, and
more seriously a very poor cell permeability index for
both Caco-2 and MDCK tests. The data seem to be consist-
ent with the widely reported poor bioavailability of curcu-
min. FLLL-11, FLLL-12 and GO-Y030 all have favorable
drug-likeness profiles. However, the relatively minor con-
cerns are: 1) FLLL-11 has subpar cell permeability indexes
(Caco2: 485; MDCK: 226), not as good as FLLL-12
(Caco2: 1164; MDCK: 583) and GO-Y030 (Caco2: 3073;
MDCK: 1665); 2) the IC50 HERG K+ blockage index for all
three compounds are on borderline as all three com-
pounds have QPlogHERG values around -5.5, below the -
5 redline. Optimization to lessen this seems needed; 3)
GO-Y030 has poor oral absorption index (index as 1 for
low absorption) compared to FLLL-11 and FLLL-12 (both
indexes as 3 for high oral absorption). In addition, most
indicators show that GO-Y030 has the more deviations
Table 1: The IC50 (μM) of curcumin and its analogues, GO-Y030, 
FLLL-11, and FLLL-12 in human colon cancer cells and WI-38 
human lung fibroblasts
HCT116
(IC50 μM)
HT-29
(IC50 μM)
SW480
(IC50 μM)
WI-38
(IC50 μM)
Curcumin 10.91 13.31 10.26 48.82
GO-Y030 0.61 0.96 0.51 13.78
FLLL-11 2.07 4.48 1.64 >1000.00
FLLL-12 2.49 3.35 1.17 >1000.00
*Cancer cells were treated for 72 hours and cell viability was 
determined by MTT assays and IC50 values were analyzed.BMC Cancer 2009, 9:99 http://www.biomedcentral.com/1471-2407/9/99
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Curcumin and its analogues, GO-Y030, FLLL-11, and FLLL-12 induced PARP and/or caspase-3 cleavages in (A) HCT116, (B)  HT-29, (C) SW480 human colorectal cancer cells, (D) WI-38 and MCF-10A cells, (E) normal human and colonic bladder  smooth muscle cells Figure 3
Curcumin and its analogues, GO-Y030, FLLL-11, and FLLL-12 induced PARP and/or caspase-3 cleavages in (A) 
HCT116, (B) HT-29, (C) SW480 human colorectal cancer cells, (D) WI-38 and MCF-10A cells, (E) normal 
human and colonic bladder smooth muscle cells. Colorectal cancer cells and normal human cells were treated for 24 
hours. Western blot was used to detect the PARP cleavages using antibodies against cleaved PARP and cleaved caspase-3 (Cell 
Signaling Technology, Beverly, MA). The same membranes were analyzed with a 1:1000 dilution of anti-GAPDH monoclonal 
antibody (Chemicon International, Inc., Temecula, CA).
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from existing drugs than FLLL-11 and FLLL-12. Overall
evaluations show that FLLL-12 has the closest drug-like-
ness profile and has 86% similarity to propafenone and
trimethobenzamide averaged over all fifty parameters.
Therefore, it will be of interest to evaluate the inhibitory
efficacy of these curcumin analogues in tumor model in
vivo and in vivo pharmacokinetics in the future.
Conclusion
Our results demonstrated that the curcumin analogues,
GO-Y030, FLLL-11, and FLLL-12 are more potent than
curcumin in the inhibition of cell proliferation and in the
induction of apoptosis in three different human colorectal
cancer cells. GO-Y030, FLLL-11, and FLLL-12 pass the
drug-likeness test, with FLLL-12 having the highest drug-
likeness. Therefore, GO-Y030, FLLL-11, and FLLL-12 have
the translational potential as novel cancer therapeutic or
preventive agents for human colorectal carcinoma and
deserve the further evaluation.
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